[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610735":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":11,"studyPopulation":11,"armGroups":29,"interventions":40,"overallOfficials":50,"centralContacts":54,"locations":60,"responsibleParty":78,"collaborators":11,"id":80,"slug":11,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":11,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":11,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":11,"overallStatus":63,"whyStopped":11,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Number of Participants Experiencing Dose-limiting toxicities (DLTs)",null,"Up to Day 28",{"measure":14,"description":11,"timeFrame":15},"Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)","Up to 2 Years",[17,19,21],{"measure":18,"description":11,"timeFrame":15},"Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",{"measure":20,"description":11,"timeFrame":15},"Maximum Serum Concentration (Cmax) of ZG006",{"measure":22,"description":11,"timeFrame":15},"Area Under the Concentration-time Curve (AUC) Over the Dosing Interval for ZG006",{"allocation":24,"interventionModel":25,"interventionModelDescription":11,"primaryPurpose":26,"observationalModel":11,"timePerspective":11,"maskingInfo":27},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":28,"maskingDescription":11,"whoMasked":11},"NONE",[30,37],{"label":31,"type":32,"description":33,"interventionNames":34},"Part 1：Group A","EXPERIMENTAL","ZG006 Q3W",[35,36],"Drug: ZG006","Drug: Serplulimab",{"label":38,"type":32,"description":33,"interventionNames":39},"Part 1：Group B",[35,36],[41,46],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":11},"DRUG","ZG006","ZG006 will be administered as an IV infusion.",[31,38],{"type":42,"name":47,"description":48,"armGroupLabels":49,"otherNames":11},"Serplulimab","Serplulimab will be administered as an IV infusion.",[31,38],[51],{"name":52,"affiliation":5,"role":53},"Jason Wu","STUDY_CHAIR",[55],{"name":56,"role":57,"phone":58,"phoneExt":11,"email":59},"Cong Zhang","CONTACT","17602176888","zhangc@zelgen.com",[61],{"facility":62,"status":63,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"Shanghai Chest Hospital","RECRUITING","Shanghai","Shanghai Municipality","200030","China","CN",{"type":70,"coordinates":71},"Point",[72,73],121.45806,31.22222,{"lat":73,"lon":72},[76],{"name":77,"role":57,"phone":11,"phoneExt":11,"email":11},"Shun Lu",{"type":79,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610735",false,"NCT07231445","Study of ZG006 in Combination With PD-1\u002FPD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer","A Phase Ib Study Evaluating the Safety and Efficacy of ZG006 in Combination With PD-1\u002FPD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer","Inclusion Criteria:\n\n* Participants with histologically or cytologically confirmed ES-SCLC.\n* Fully understand the study and voluntarily sign the informed consent form;\n* Male or female 18\\~75 years of age;\n* Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;\n* Life expectancy ≥ 3 months;\n\nExclusion Criteria:\n\n* Participants were deemed unsuitable for participating in the study by the investigator for any reason.","ALL","18 Years","75 Years",{"count":90,"type":91},100,"ESTIMATED","INTERVENTIONAL",[94],"PHASE1","This is a randomized, multicenter, phase Ib study to evaluate the safety and efficacy of ZG006 combined with PD-1\u002FPD-L1 immune checkpoint inhibitors (±chemotherapy) as first-line therapy in Participants with extensive stage small cell lung cancer.",[97],"Small Cell Lung Cancer","2026-04-27",{"date":100,"type":101},"2026-04-28","ACTUAL",{"date":103,"type":101},"2026-04-21",{"date":105,"type":91},"2028-12",{"name":5,"class":6},1]